MGMT-UNMETHYLATED GLIOBLASTOMA
Clinical trials for MGMT-UNMETHYLATED GLIOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new MGMT-UNMETHYLATED GLIOBLASTOMA trials appear
Sign up with your email to follow new studies for MGMT-UNMETHYLATED GLIOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy takes on deadly brain cancer
Disease control Recruiting nowThis study tests a drug called WP1066 combined with radiation therapy for people with a newly diagnosed aggressive brain cancer called glioblastoma. The drug targets a protein that helps the tumor grow and hide from the immune system, while radiation kills cancer cells. The goal …
Matched conditions: MGMT-UNMETHYLATED GLIOBLASTOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 17, 2026 05:48 UTC
-
Engineered immune cells take on deadly brain tumors in new trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called E-SYNC CAR T cells for people with a specific form of glioblastoma, an aggressive brain cancer. The therapy involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack the tumor, and infu…
Matched conditions: MGMT-UNMETHYLATED GLIOBLASTOMA
Phase: PHASE1 • Sponsor: Hideho Okada, MD, PhD • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for brain cancer: experimental virus therapy targets aggressive gliomas
Disease control Recruiting nowThis study tests whether adding two experimental drugs, DB107-RRV and DB107-FC, to standard treatment (radiation and chemotherapy) can help people with newly diagnosed high grade glioma, a fast-growing brain cancer. About 70 adults aged 18-75 will receive the drugs during and aft…
Matched conditions: MGMT-UNMETHYLATED GLIOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Could a new drug combo extend life in aggressive brain cancer?
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard treatment (radiation and temozolomide) helps people with newly diagnosed glioblastoma live longer. About 190 adults will be randomly assigned to receive either the standard treatment alone or standard treatment plus…
Matched conditions: MGMT-UNMETHYLATED GLIOBLASTOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC